Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biomarin Pharmaceuticals
(NQ:
BMRN
)
83.91
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biomarin Pharmaceuticals
< Previous
1
2
3
4
5
6
7
Next >
10 Biggest Price Target Changes For Monday
April 25, 2022
Keybanc cut Salesforce, Inc. (NYSE: CRM) price target from $281 to $223. Salesforce shares fell 1.1% to $169.60 in pre-market trading.
Via
Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
April 24, 2022
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering...
Via
Benzinga
A Bearish Sign Appears On Biomarin Pharmaceutical's Chart
April 21, 2022
If history is any guide, there may be trouble ahead for shares of Biomarin Pharmaceutical (NASDAQ:BMRN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish...
Via
Benzinga
BioMarin Stock Dives As FDA Questions The Safety Of Its Gene Therapy
February 18, 2022
BioMarin needs to run additional testing in animal models for its PKU gene therapy.
Via
Investor's Business Daily
BioMarin Sells Priority Review Voucher For $110M
February 09, 2022
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) has agreed to sell the Rare Pediatric Disease Priority Review Voucher (PRV)
Via
Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
April 21, 2022
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company.
Via
InvestorPlace
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
February 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...
Via
Benzinga
BioMarin Clocks Flat Q4 Sales Despite Erosion oF US Kuvan Market
February 24, 2022
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) reported a 1% Y/Y decrease in Q4 revenue to $449.8 million, beating the consensus estimate of $442.39 million. The decline...
Via
Benzinga
Recap: Biomarin Pharmaceutical Q4 Earnings
February 23, 2022
Biomarin Pharmaceutical (NASDAQ:BMRN) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement....
Via
Benzinga
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
February 23, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase...
Via
Benzinga
FDA Asks For More Data To Resolve BioMarin's Gene Therapy Clinical Hold
February 18, 2022
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) said that the FDA had requested additional information regarding the clinical hold on PHEARLESS Phase 1/2 study of BMN...
Via
Benzinga
Bear Market Bets In Biotech
February 07, 2022
Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020.
Via
Talk Markets
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...
Via
Benzinga
Futures Resume Tumbling After Yields Spike To New 2 Year High
January 10, 2022
US index futures traded down to session lows as US traders sat at their desks after rising modestly earlier in the session, and were down 27 points or 0.6% at 730am.
Via
Talk Markets
BioMarin's Hemophilia Gene Therapy Meets Efficacy Endpoints At Two Year Analysis
January 10, 2022
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) announced results from its ongoing Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, investigational gene therapy for severe...
Via
Benzinga
This Favorable Sign Appears On Biomarin Pharmaceutical's Chart
November 25, 2021
If history is any guide, there may be good fortune ahead for shares of Biomarin Pharmaceutical (NASDAQ:BMRN). A so-called "golden cross" has formed on its chart and, not...
Via
Benzinga
Hopeful Golden Cross Forms On Biomarin Pharmaceutical's Chart
November 24, 2021
If history is any guide, there may be good fortune ahead for shares of Biomarin Pharmaceutical (NASDAQ:BMRN). A so-called "golden cross" has formed on its chart and, not...
Via
Benzinga
Where Biomarin Pharmaceutical Stands With Analysts
November 22, 2021
Over the past 3 months, 6 analysts have published their opinion on Biomarin Pharmaceutical (NASDAQ:
Via
Benzinga
10 Biggest Price Target Changes For Monday
November 22, 2021
MKM Partners cut Activision Blizzard, Inc. (NASDAQ:A...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 22, 2021
November 22, 2021
Upgrades According to Evercore ISI Group, the prior rating for Kimco Realty Corp (NYSE:
Via
Benzinga
Why BioMarin Pharmaceutical Stock Jumped by 10.3% on Friday
November 20, 2021
The rare-disease specialist might now have a true franchise-level drug following the approval of Voxzogo.
Via
The Motley Fool
Exposures
Product Safety
BioMarin Stock Jumps As FDA Approval Unlocks Its 'Next Growth Inflection'
November 19, 2021
The BioMarin drug treats achondroplasia, a form of short-limbed dwarfism.
Via
Investor's Business Daily
Exposures
Product Safety
FDA Conditionally Approves Biomarin's Dwarfism Drug
November 19, 2021
The FDA has approved BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Voxzogo (vosoritide) for Injection for achondroplasia. The approval comes for achondroplasia...
Via
Benzinga
Exposures
Product Safety
Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar?
November 18, 2021
Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
November 02, 2021
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a...
Via
Benzinga
BioMarin's Q3 Net Income Hit By Lower Product Sales
October 28, 2021
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) reported a 14% Y/Y decrease in Q3 revenue to $408.7 million, missing the consensus estimate of $435.32 million. The decline...
Via
Benzinga
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
November 14, 2021
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at...
Via
Benzinga
Exposures
Product Safety
BioMarin Pharmaceutical inc (BMRN) Q3 2021 Earnings Call Transcript
October 28, 2021
BMRN earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Biomarin Pharmaceutical: Q3 Earnings Insights
October 27, 2021
Biomarin Pharmaceutical (NASDAQ:BMRN) reported its Q3 earnings results on Wednesday, October 27, 2021 at 04:05 PM. Here's what investors need to know about the announcement....
Via
Benzinga
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
October 24, 2021
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.